NeoTYPE™ Cancer Profiles are multi-method test panels, custom-designed for a specific tumor type, that identify the genetic changes most significant to therapy decisions, prognosis, and clinical research. Read more.
This test is performed by sequencing of select exons of the genes listed. ASXL1, BRAF, CEBPA, DNMT3A, ETV6, FLT3, HRAS, IDH1, IDH2, JAK2 V617F, JAK2 Exon 12+14, KRAS, MLL, NPM1, NRAS, PDGFRA, PHF6, PTPN11, RUNX1, SETBP1, TET2, TP53 and WT1. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together. Any tests may be ordered separately; these will be reported individually without summary interpretation. The AML Prognostic Profile may also be ordered as reflex after intermediate cytogenetics in the AML Reflex Panel (see separate AML Reflex Panel listing).
For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoTYPE MDS/CMML Profile.